In vitro antibacterial activity of the peptide deformylase inhibitor BB-83698

Journal of Antimicrobial Chemotherapy

Volumn 53, Issue 4, 2004, Pages 664-668

  Lofland, Denene ^a   Difuntorum, Stacey ^a   Waller, Andrew ^b   Clements, John M ^b   Weaver, Mellany K ^c   Karlowsky, James A ^c   Johnson, Kirk ^a  

^a Genesoft Pharmaceuticals Inc   (United States)

^b British Biotech Pharmaceuticals Ltd   (United Kingdom)

^c Focus Technologies Incorporated   (United States)

Author keywords

Antibiotics; Antimicrobials; Bactericidal; MBC; MIC

Indexed keywords

AMOXICILLIN PLUS CLAVULANIC ACID; CEFTRIAXONE; COTRIMOXAZOLE; DALFOPRISTIN PLUS QUINUPRISTIN; ERYTHROMYCIN; GENTAMICIN; LEVOFLOXACIN; LINEZOLID; N [1 TERT BUTYL 2 OXO 2 [4 (2 THIAZOLYLMETHYL) 1 PIPERAZINYL]ETHYL] 3 CYCLOPENTYL 2 (N FORMYL N HYDROXYAMINOMETHYL)PROPIONAMIDE; OXACILLIN; PENICILLIN G; PEPTIDE DEFORMYLASE INHIBITOR; TETRACYCLINE; UNCLASSIFIED DRUG; VANCOMYCIN;

ALPHA HEMOLYTIC STREPTOCOCCUS; ANTIBACTERIAL ACTIVITY; ANTIBIOTIC RESISTANCE; ANTIBIOTIC SENSITIVITY; ARTICLE; BACTERIAL COUNT; BACTERIAL STRAIN; BACTERIUM ISOLATE; CONTROLLED STUDY; DILUTION; DRUG POTENCY; HAEMOPHILUS INFLUENZAE; IN VITRO STUDY; MINIMUM INHIBITORY CONCENTRATION; MORAXELLA CATARRHALIS; MULTIDRUG RESISTANCE; NONHUMAN; PHENOTYPE; PRACTICE GUIDELINE; STAPHYLOCOCCUS AUREUS; STREPTOCOCCUS; STREPTOCOCCUS AGALACTIAE; STREPTOCOCCUS PNEUMONIAE; STREPTOCOCCUS PYOGENES;

AMIDOHYDROLASES; ANTI-BACTERIAL AGENTS; DRUG RESISTANCE, BACTERIAL; ENZYME INHIBITORS; HAEMOPHILUS INFLUENZAE; HUMANS; HYDROXAMIC ACIDS; MICROBIAL SENSITIVITY TESTS; MORAXELLA (BRANHAMELLA) CATARRHALIS; STAPHYLOCOCCUS AUREUS; STREPTOCOCCUS PNEUMONIAE;

EID: 1642373345     PISSN: 03057453     EISSN: None     Source Type: Journal    
DOI: 10.1093/jac/dkh129     Document Type: Article

References (11)

1. Clements, J., Beckett, R., Brown, A. et al. (2001). Antibiotic activity and characterization of BB-3497, a novel peptide deformylase inhibitor. Antimicrobial Agents and Chemotherapy 45, 563-70.
2. Yuan, Z., Trias, J. & White, R. (2001). Deformylase as a novel antibacterial target. Drug Discovery Today 6, 954-61.
3. Giglione, C., Pierre, M. & Meinnel, T. (2000). Peptide deformylase as a target for new generation, broad spectrum antimicrobial agents. Molecular Microbiology 36, 1197-205.
4. Jones, R. & Rhomberg, P. (2003). Comparative spectrum and activity of NVP-PDF386 (VRC4887), a new peptide deformylase inhibitor. Journal of Antimicrobial Chemotherapy 51, 157-61.
5. Wise, R., Andrews, J. & Ashby, J. (2002). In vitro activities of peptide deformylase inhibitors against gram-positive pathogens. Antimicrobial Agents and Chemotherapy 46, 1117-8.
6. Nguyen, K., Colton, C., Chakrabarti, R. et al. (2003). Characterization of a human peptide deformylase: implications for antibacterial drug design. Biochemistry 42, 9952-8.
7. National Committee for Clinical Laboratory Standards. (2003). Methods for Dilution Antimicrobial Susceptibility Tests for Bacteria that Grow Aerobically - Fifth Edition: Approved Standard M7-A6. NCCLS, Wayne, PA, USA.
8. National Committee for Clinical Laboratory Standards. (1999). Methods for Determining Bactericidal Activity of Antimicrobial Agents: Approved Standard M26-A. NCCLS, Wayne, PA, USA.
9. Hackbarth, C., Chen, D., Lewis, J. et al. (2002). N-alkyl urea hydroxamic acids as a new class of peptide deformylase inhibitors with antimicrobial activity. Antimicrobial Agents and Chemotherapy 46, 2752-64.
10. Azoulay-Dupuis, E., Mohler, J., Rieux, V. et al. (2001). Efficacy of BB-83698 a novel peptide deformylase inhibitor, in a mouse pneumonia model induced by wild type and antimicrobial-resistant Streptococcus pneumoniae. In Program and Abstracts of the Forty-first Interscience Conference on Antimicrobial Agents and Chemotherapy, Chicago, IL, 1990. Abstract F-354, p. 206. American Society for Microbiology, Washington, DC, USA.
11. Craig, W. & Andes, D. (2001). In vivo pharmacodynamics of BB-83698, a deformylase inhibitor. In Program and Abstracts of the Forty-first Interscience Conference on Antimicrobial Agents and Chemotherapy, Chicago, IL, 1990. Abstract F-355, p. 206. American Society for Microbiology, Washington, DC, USA.